ABSTRACT
INTRODUCTION Alzheimer’s disease (AD) is a neurodegenerative condition characterised by amyloid plaque accumulation and neurofibrillary tangles. Early detection is essential for effective intervention, but current diagnostic methods that enable early diagnosis in clinical practice rely on invasive or costly biomarker scanning. This study aimed to explore the utility of 7T MRI in assessing hippocampal subfield volumes and their correlation with cerebrospinal fluid (CSF) biomarkers in prodromal AD. METHODS: Fifty-six participants, including AD patients and healthy controls, underwent 7T MRI scanning. Automated segmentation delineated hippocampal subfield volumes, with subsequent normalization to whole brain volume.
RESULTS Significant differences in hippocampal and subfield volumes were observed in prodromal AD patients, even when they did not exhibit high MTA scores on 3T MRI or show any whole brain volume loss. Additionally, the volume of the entorhinal cortex (ERC) correlated significantly with CSF amyloid-β levels, suggesting ERC’s potential as a proxy CSF amyloid-ß measurement. Conversely, no significant associations were found between CSF 181-phospho-tau or total tau levels and any hippocampal subfield volumes.
DISCUSSION These findings show the potential use of 7T MRI, particularly in ERC assessment, as a biomarker for early AD identification. Further validation studies are warranted to confirm these results and elucidate the relationship of ERC volume with CSF biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://clinicaltrials.gov/study/NCT04992975?cond=NCT04992975&rank=1
Funding Statement
This study is funded by the Medical Research Council, UK (grant MR/T005580/1) through Clinical Academic Partnership Award to AAH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project received favourable opinion from the East Midlands-Nottingham 2 research Ethics committee (reference: 20/EM/0023) and the UK Health Research Authority (IRAS:276174). The committee is constituted in accordance with the Governance Arrangement for research Ethics committee and complies fully with the Standard Operating Procedures for Research Ethics Committee in the UK
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is Available on request
